Is It Time to Rethink Standard Anticoagulation? Apixaban vs VKA in HeartMate 3 LVADs
Tania Ahuja, Clinical Assistant Professor, Assistant Director of Clinical Pharmacy and Clinical Pharmacotherapy Specialist, shared a post on X:
”Is it time to re-think anticoagulation for HeartMate3 (HM3) LVADs?
2 RCTs and 3 observational studies including 209 patients: 119 in the apixaban group and 90 in the VKA group demonstrating apixaban just as good as VKA and with less.”
Read the full article here.
Title: Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis
Authors: Andrea Tripoli, Miguel A. Samaniego, Norma N. Gamarra-Valverde, Shivraj Paneer Selvam, Edgardo Kaplinsky, Alejandro Barbagelata, Anna Mara Scandroglio, Juliana Giorgi
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera